Ocular Therapeutix (OCUL) Inventory Average (2014 - 2026)
Ocular Therapeutix's quarterly Inventory Average came in at $3.7 million in Q1 2026, up 15.72% year-on-year from $3.2 million in Q1 2025, and up 3.53% quarter-over-quarter from $3.5 million in Q4 2025.
Ocular Therapeutix has reported Inventory Average for 13 years, with the latest figure at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Inventory Average rose 15.72% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 15.72% YoY), and the FY2025 full-year result was $3.3 million, up 23.55% from the prior year.
- Inventory Average for Q1 2026 stood at $3.7 million, up from $3.5 million in the prior quarter.
- The five-year high for Inventory Average was $3.7 million in Q1 2026, with the low at $1.3 million in Q1 2022.
- Average Inventory Average over 5 years is $2.5 million, with a median of $2.4 million recorded in 2024.
- Year-over-year, Inventory Average jumped 62.58% in 2023 and rose 11.01% in 2024.
- Tracing OCUL's Inventory Average over 5 years: stood at $1.8 million in 2022, then grew by 29.64% to $2.3 million in 2023, then increased by 19.36% to $2.7 million in 2024, then climbed by 29.51% to $3.5 million in 2025, then grew by 3.53% to $3.7 million in 2026.
- The last three Inventory Average figures came in at $3.7 million (Q1 2026), $3.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.59 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.15 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 83.37 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.65 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.17 Mn |
| Jun 30, 2021 | 1.12 Mn |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 1.18 Mn |
| Sep 30, 2020 | 1.11 Mn |
| Jun 30, 2020 | 1.09 Mn |
| Mar 31, 2020 | 1.03 Mn |
| Dec 31, 2019 | 924,500.00 |
| Sep 30, 2019 | 828,500.00 |
| Jun 30, 2019 | 513,500.00 |
| Mar 31, 2019 | 241,000.00 |
| Dec 31, 2018 | 159,500.00 |
| Sep 30, 2018 | 116,500.00 |
| Jun 30, 2018 | 135,000.00 |
| Mar 31, 2018 | 130,500.00 |
| Dec 31, 2017 | 124,500.00 |
| Sep 30, 2017 | 108,500.00 |
| Jun 30, 2017 | 93,000.00 |
| Mar 31, 2017 | 104,500.00 |
| Dec 31, 2016 | 119,500.00 |
| Sep 30, 2016 | 137,500.00 |
| Jun 30, 2016 | 138,000.00 |
| Mar 31, 2016 | 130,500.00 |
| Dec 31, 2015 | 140,500.00 |
| Sep 30, 2015 | 146,000.00 |
| Jun 30, 2015 | 151,500.00 |
| Mar 31, 2015 | 145,500.00 |
| Dec 31, 2014 | 125,000.00 |
| Sep 30, 2014 | 113,000.00 |